Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Swiss Cancer Institute
Intergroupe Francophone de Cancerologie Thoracique
National Cancer Institute (NCI)
Gustave Roussy, Cancer Campus, Grand Paris
University of Texas Southwestern Medical Center
Latin American Cooperative Oncology Group
AstraZeneca
Weill Medical College of Cornell University
AIO-Studien-gGmbH
Fundación GECP
Incyte Corporation
AstraZeneca
MedImmune LLC
Pharmacyclics LLC.